UPDATE: First Wave BioPharma, Inc. (FWBI) PT Lowered to $25 at Roth Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. NDAQ

Go back to UPDATE: First Wave BioPharma, Inc. (FWBI) PT Lowered to $25 at Roth Capital

First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract

August 31, 2022 7:00 AM EDT

BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, announced today that an abstract titled, Formulation Development of Enterically Protected Spray Dried Dispersions of Adrulipase, has been accepted at AAPS 2022 PharmSci 360. The conference will be held Oct. 16-19 at the Boston Convention... More

First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022

August 29, 2022 7:00 AM EDT

BOCA RATON, Fla., Aug. 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, will present at the 2022 H.C. Wainwright 24th Annual Global Investment Conference. The conference is taking place September 12-14, 2022, at the Lotte New York Palace Hotel, New York City.

Details of the... More